pyrimidin-5-ylmethyl methanesulfonate | 920023-38-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: pyrimidin-5-ylmethyl methanesulfonate
• 英文别名: Methanesulfonic acid pyrimidin-5-ylmethyl ester
• CAS: 920023-38-7
• 化学式: C₆H₈N₂O₃S
• 分子量: 188.207
• InChiKey: FOMJVJVVZVGYMS-UHFFFAOYSA-N

物化性质

• 沸点：
  394.5±25.0 °C(Predicted)
• 密度：
  1.382±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  77.5
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  pyrimidin-5-ylmethyl methanesulfonate 在 potassium carbonate 、 溶剂黄146 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 32.5h， 生成 (1-((7-((2-methyl-[1,1'-biphenyl]-3-yl)methoxy)-5-(pyrimidin-5-ylmethoxy)-2,3-dihydro-1H-inden-4-yl)methyl)azetidin-2-yl)methanol
  参考文献：
  名称：

  [EN] COMPOUNDS AS PD1/PD-L1 INHIBITORS AND METHODS THEREOF
  [FR] COMPOSÉS UTILISÉS EN TANT QU'INHIBITEURS DE PD1/PD-L1 ET PROCÉDÉS ASSOCIÉS

  摘要：

  The present invention relates in general, to the field of pharmaceutical compounds, more particularly to the compounds of Formula (I) which acts as inhibitors for PD1/PD-L1 interaction. The present invention further relates to a method of preparation of compounds of Formula (I). The present invention also relates to a composition of compounds of Formula (I).

  公开号：

  WO2022224278A1
• 作为产物：
  描述：

  嘧啶-5-甲醛 在 lithium aluminium tetrahydride 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 pyrimidin-5-ylmethyl methanesulfonate
  参考文献：
  名称：

  4,5-二取代的嘧啶的制备：5-甲磺酰氧基嘧啶的环取代

  摘要：

  DOI：

  10.1021/jo001316s

文献信息

• Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists
  申请人：Bissantz Caterina

  公开号：US20070027173A1

  公开（公告）日：2007-02-01

  The invention relates to indol-3-yl-carbonyl-spiro-piperidine derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the spiro-piperidine head group A and the residues R 1 , R 2 and R 3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, methods for preparing the compounds and pharmaceutical compositions, and their use in the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.

  本发明涉及作为V1a受体拮抗剂的吲哚-3-基-甲酰基-螺环-哌啶衍生物，其由公式I表示：其中，螺环-哌啶头基A以及残基R1、R2和R3如本文所述定义。本发明进一步涉及含有此类化合物的药物组合物，制备化合物和药物组合物的方法，以及它们在治疗痛经、高血压、慢性心力衰竭、血管升压素不适当分泌、肝硬化、肾病综合征、强迫症、焦虑和抑郁障碍中的用途。
• [EN] SUBSTITUTED 4-AZAINDOLES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS<br/>[FR] 4-AZAINDOLES SUBSTITUÉS ET LEUR UTILISATION COMME MODULATEURS DU RÉCEPTEUR DE GLUN2B
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2017007938A1

  公开（公告）日：2017-01-12

  Substituted 4-azaindoles as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.

  将4-氮杂吲哚作为NR2B受体配体。这类化合物可用于NR2B受体调节以及用于治疗由NR2B受体活性介导的疾病状态、紊乱和病况的药物组合物和方法。
• [EN] SUBSTITUTED 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS<br/>[FR] 1H-IMIDAZO[4,5-B]PYRIDIN-2(3H)-ONES SUBSTITUÉES ET LEUR UTILISATION EN TANT QUE MODULATEURS DU RÉCEPTEUR GLUN2B
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2018067786A1

  公开（公告）日：2018-04-12

  Substituted 1 H-imidazo[4,5-b]pyridin-2(3H)-ones as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.

  1-取代的1H-咪唑[4,5-b]吡啶-2(3H)-酮作为NR2B受体配体。这类化合物可用于NR2B受体调节以及用于治疗由NR2B受体活性介导的疾病状态、疾病和病况的药物组合物和方法。
• [EN] INDOLES USEFUL IN THE TREATMENT OF ANDROGEN-RECEPTOR RELATED DISEASES<br/>[FR] INDOLES UTILES DANS LE TRAITEMENT DE MALADIES LIEES AU RECEPTEUR D'ANDROGENE
  申请人：AKZO NOBEL NV

  公开号：WO2004041782A1

  公开（公告）日：2004-05-21

  This invention provides non-steroidal compounds with affinity for the androgen receptor and utility for androgen-receptor related treatments, having a structure according to the formula (1) wherein X is S,SO or S02; R1 is a 5- or 6-membered monocyclic, hetero- or homocyclic, saturated or unsaturated ring structure optionally substituted with one or more substituents selected from the group consisting of halogen, CN, (1C-4C)fluoroalkyl, nitro, (1C-4C)alkyl, (1C-4C)alkoxy or (1C-4C)fluoroalkoxy; R2 is 2-nitrophenyl, 2-cyanophenyl, 2-hydroxymethyl-phenyl, pyridin-2-yl, pyridin-2-yl-N-oxide, 2-benzamide, 2-benzoic acid methyl ester or 2-methoxyphenyl; R3 is H, halogen or (1C-4C)alkyl; R4 is H, OH, (1C-4C)alkoxy, or halogen; R4 is H, OH, (1C-4C)alkoxy, NH2, CN, halogen, (1C-4C)fluoroalkyl, N02, hydroxy(1C-4C)alkyl, C02H, C02(1C-6C)alkyl, or R5 is NHR6, wherein R6 is (1C-6C)acyl optionally substituted with one or more halogens, S(O)2(1C-4C)alkyl, or S(O)2aryl optionally substituted with (1C-4C)alkyl or one or more halogens, or R5 is C(O)N(R8,R9), wherein R8 and R9 each independently are H, (3C-6C)cycloalkyl, or CH2R10, wherein R10 is H, (1C-5C)alkyl, (1C-5C)alkenyl, hydroxy(1C-3C)alkyl, (1C-4C)alkylester of carboxy(1C-4C)alkyl, (1C-3C)alkoxy(1C-3C)alkyl, (mono- or di(1C-4C)alkyl)aminomethyl, (mono- or di(1C-4C)alkyl)aminocarbonyl, or a 3-, 4-, 5- or 6-membered monocyclic, homo- or heterocyclic, aromatic or non-aromatic ring, or R8 and R9 form together with the N a heterocyclic 5- or 6-membered saturated or unsaturated ring optionally substituted with (1C-4C)alkyl; or a salt or hydrate form thereof.

  这项发明提供了与雄激素受体亲和力及用于雄激素受体相关治疗的非甾体化合物，其结构符合以下式(1)：其中X为S、SO或S02；R1为5-或6-成员单环、杂环或同环、饱和或不饱和环结构，可选地取代一个或多个取代基，所选取代基包括卤素、CN、(1C-4C)氟烷基、硝基、(1C-4C)烷基、(1C-4C)氧烷基或(1C-4C)氟烷氧基；R2为2-硝基苯基、2-氰苯基、2-羟甲基苯基、吡啶-2-基、吡啶-2-基-N-氧化物、2-苯甲酰胺基、2-苯甲酸甲酯或2-甲氧基苯基；R3为H、卤素或(1C-4C)烷基；R4为H、OH、(1C-4C)氧烷基或卤素；R4为H、OH、(1C-4C)氧烷基、NH2、CN、卤素、(1C-4C)氟烷基、N02、羟基(1C-4C)烷基、C02H、C02(1C-6C)烷基，或R5为NHR6，其中R6为(1C-6C)酰基，可选地取代一个或多个卤素、S(O)2(1C-4C)烷基，或S(O)2芳基，可选地取代(1C-4C)烷基或一个或多个卤素，或R5为C(O)N(R8,R9)，其中R8和R9各自独立地为H、(3C-6C)环烷基，或CH2R10，其中R10为H、(1C-5C)烷基、(1C-5C)烯基、羟基(1C-3C)烷基、(1C-4C)烷酯基或羧基(1C-4C)烷基、(1C-3C)氧烷基(1C-3C)烷基，(单-或双(1C-4C)烷基)氨基甲基，(单-或双(1C-4C)烷基)氨基甲酰基，或3-、4-、5-或6-成员单环、同或异环、芳香或非芳香环，或R8和R9与N一起形成一个饱和或不饱和的5-或6-成员杂环，可选地取代(1C-4C)烷基；或其盐或水合物形式。
• [EN] 2- (TERT - BUTOXY) -2- (7 -METHYLQUINOLIN- 6 - YL) ACETIC ACID DERIVATIVES FOR TREATING AIDS<br/>[FR] DÉRIVÉS D'ACIDE 2-(TERT-BUTOXY)-2-(7-MÉTHYLQUINOLÉIN-6-YL)ACÉTIQUE POUR TRAITER LE SIDA
  申请人：GILEAD SCIENCES INC

  公开号：WO2013103724A1

  公开（公告）日：2013-07-11

  The invention provides compounds and salts thereof as d herein. The invention also provides pharmaceutical compositions comprising a compound disclosed herein, processes for preparing compounds disclosed herein, intermediates useful for preparing compounds disclosed herein and therapeutic methods for treating an HIV infection, treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS or ARC symptoms in a mammal using compounds disclosed herein.

  本发明提供作为d的化合物及其盐。本发明还提供包括本文所披露的化合物的药物组合物，用于制备本文所披露的化合物的方法，用于制备本文所披露的化合物的有用中间体，以及使用本文所披露的化合物治疗HIV感染、治疗HIV病毒的增殖、治疗艾滋病或延缓哺乳动物发生艾滋病或ARC症状的治疗方法。